Robotic Transplant an Option for Obese Kidney Patients
The findings should allow more obese patients to receive kidney transplants.
Patients with a body mass index (BMI) greater than 35 who have end-stage kidney disease are often denied transplantation, and patients with a BMI over 40 often die on dialysis without an opportunity for transplant. Obesity "markedly increases the risk of wound infection, which lowers graft and patient survival," said Dr. Jose Oberholzer, chief of transplantation surgery at University of Illinois Hospital and lead author of the study, in the March issue of the American Journal of Transplantation.
Minimally invasive robotic transplantation may reduce health disparities for obese patients with end-stage kidney disease, according to the study authors.
Up to half of dialysis patients are obese, defined as having a body mass index greater than 30. Studies have shown that obese patients with chronic kidney failure wait longer for transplants and consequently have poorer outcomes than non-obese patients. However, obese transplant patients who don't have surgical site infections have similar kidney transplant success rates as non-obese patients.
Obese patients often have diabetes and hypertension as a result of being overweight. Seventy percent of hypertensive dialysis patients and 75 percent of diabetic dialysis patients survive less than five years, previous research has shown.
University of Illinois Hospital surgeons have developed a new robotic technique that avoids any incision in the infection-prone lower abdomen and uses only a small incision above the belly-button.
Physicians identified 28 obese patients who received robotic kidney transplants at UI Hospital between June 2009 and December 2011. They followed the patients for six months after transplant and compared their outcomes with a group of 28 obese patients who received traditional "open" kidney transplantation at the hospital prior to 2009.
There were no surgical site infections in the robotic patients, while 29 percent of patients in the control group developed an infection. Measurements of kidney function, graft and patient survival were comparable in the two groups.
Source: University of Illinois Hospital & Health Sciences System
Published on : Tue, 21 May 2013
Print as PDF
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery.All blood-contact surfaces of the NovaPort cannulas are coated with the bio- and...
Monitor vital signs of sensitive patients with reliable, smart and intuitive technology Not available in the US Sensitive patients, like neonates, require comfortable care. With transcutaneous monitoring, you can easily keep track of the oxygenation...
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d